Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination

Lenanrt Friis-Hansen500 enrolled

Overview

The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents, Persons Vaccinated With Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1 nCov-19 AZD1222 Vaccines, and Convalescent COVID-19 Patients That Have Subsequently Been Vaccinated. A Potential Difference in the Immunoglobulin Concentrations of the Pfizer-BioNTech BNT162b2 Vaccine, Moderna mRNA-1273 vaccine and the AstraZeneca ChAdOx1-S Vaccine Will be Uncovered. This Knowledge About the Mucosal Immunity Will be Important for Further Designing of Vaccine Strategies.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Covid19

Interventions

Blood- and saliva testsDIAGNOSTIC_TEST

Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Both Hospital staff as well as non-health care workers will be invited to participate Exclusion Criteria: * Individuals not fulfilling the inclusion criteria or declining blood or saliva collection. * Exclusion criteria are neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using Salivette.

Outcomes

Primary Outcomes

Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma

Detection of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma in participants who have been infected with COVID-19, vaccinated with Pfizer-BioNTech/Moderna mRNA-1273/AstraZeneca or infected and vaccinated

Time frame: Between 21 and 200 days after infection/vaccination

Secondary Outcomes